BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) reported its Q3 FY2025 financial results with organic revenue growth of 6% to $316.2 million. The company's GAAP EPS decreased to $0.14 from $0.31 year-over-year, while adjusted EPS improved to $0.56 from $0.48. The Protein Sciences segment showed strong performance with 7% organic growth to $227.7 million, driven by improved pharma end market conditions. The Diagnostics and Spatial Biology segment grew 2% to $89.2 million. The company achieved an adjusted operating margin of 34.9%, up from 33.0% in the prior year, benefiting from profitability initiatives and volume leverage. However, GAAP operating margin declined to 12.2% from 22.1%, impacted by a non-recurring arbitration award.

Positive

• Organic revenue increased 6% to $316.2 million
• Adjusted EPS grew to $0.56 from $0.48 year-over-year
• Protein Sciences segment showed strong 7% organic growth
• Improved adjusted operating margin to 34.9% from 33.0%
• Strong performance in cell therapy and protein analysis instrumentation businesses

Negative

• GAAP EPS declined to $0.14 from $0.31 year-over-year
• GAAP operating margin decreased to 12.2% from 22.1%
• Non-recurring arbitration award negatively impacted operating margin
• Foreign currency exchange had unfavorable 1% impact on revenue

Insights

Financial Analyst

Bio-Techne delivered 6% organic growth and improved adjusted profitability, but GAAP results declined significantly due to a one-time arbitration award.

Bio-Techne's Q3 FY2025 results present a tale of two metrics - solid organic growth and improved adjusted profitability, balanced against significantly weaker GAAP performance.

The company achieved 6% organic revenue growth (4% reported) to $316.2 million, demonstrating resilience in what management describes as a "dynamic macroenvironment." However, GAAP earnings performance declined substantially, with EPS falling to $0.14 from $0.31 year-over-year, and GAAP operating income decreasing 42% to $38.7 million.

This significant gap between reported and adjusted results stems primarily from a non-recurring arbitration award that substantially impacted profitability metrics. On an adjusted basis, results were considerably stronger - adjusted EPS increased 17% to $0.56, and adjusted operating margin expanded 190 basis points to 34.9%.

Segment performance reveals divergent trajectories within the business. The Protein Sciences segment, representing approximately 72% of total revenue, delivered 7% organic growth and margin expansion to 45.6%. Management attributed this performance to improving pharmaceutical end markets, particularly from large pharma partners, and strong execution in protein analysis instrumentation.

Meanwhile, the Diagnostics and Spatial Biology segment grew more modestly at 2% organic growth with stable operating margins of 9.4%, highlighting the substantial profitability gap between the company's two main business units.

The company's adjusted operating margin improvement to 34.9% reflects successful execution of profitability initiatives and operational leverage from volume growth. However, this was overshadowed on a GAAP basis by the arbitration impact, which compressed reported operating margins to 12.2% from 22.1% in the prior year.

Foreign currency exchange had a 1% unfavorable impact on results, as did non-recurring prior year revenue from a business held-for-sale, slightly dampening the reported growth figures.

New CEO Kim Kelderman highlighted the company's geographic and end-market positioning while noting continued execution on profitability initiatives. The results suggest Bio-Techne is navigating a gradually improving research funding environment while maintaining focus on operational efficiency.

MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025.

Third Quarter FY2025 Highlights

• Third quarter organic revenue increased by 6% (4% reported) to $316.2 million.
  
  
• GAAP earnings per share (EPS) was $0.14 versus $0.31 one year ago. Delivered adjusted EPS of $0.56 compared to $0.48 one year ago.
  
  
• Improved pharma end market conditions, combined with strong commercial execution in Protein Sciences led to 7% organic growth (6% reported) in the segment.
  
  
• Delivered adjusted operating margin of 34.9% (12.2% reported) compared to 33.0% (22.1% reported) in the prior year driven by profitability initiatives and volume leverage.

The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). Adjusted diluted EPS, adjusted net earnings, adjusted gross margin, adjusted operating income, adjusted tax rate, organic revenue, adjusted operating margin, earnings before interest, taxes, depreciation, and amortization (EBITDA), and adjusted EBITDA are non-GAAP measures that exclude certain items detailed later in this press release under the heading "Use of non-GAAP Adjusted Financial Measures." A reconciliation of GAAP to non-GAAP financial measures is included in this press release.

"Despite a dynamic macroenvironment, the Bio-Techne team once again executed at a high level and delivered strong third quarter results," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our pharma end market continued to improve, especially from our large pharma partners, which led to a solid performance in our cell therapy and protein analysis instrumentation businesses. Our continued focus on profitability resulted in a 34.9% adjusted operating margin, an increase of 190 basis points compared to the prior year period."

Kelderman added, "Our business remains well positioned both geographically and by end market, which paired with our experienced leadership team will enable the Company to successfully navigate the current operating environment. The portfolio we have built over the last five decades unlocks the scientific discoveries and diagnostic solutions that improve the quality of life and enable our differentiated financial performance."

Bio-Techne will host an earnings conference call today, May 7, 2025, at 8:00 a.m. CDT. To listen, please dial 1-877-407-9208 or 1-201-493-6784 (for international callers), and reference conference ID 13753150. The earnings call can also be accessed via webcast through the following link https://investors.bio-techne.com/ir-calendar.

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13753150. The replay will be available from 11:00 a.m. CDT on Wednesday, May 7, 2025, until 11:00 p.m. CDT on Saturday, June 7, 2025.

Third Quarter Fiscal 2025

Revenue

Net sales for the third quarter increased 4% to $316.2 million. Organic revenue increased 6% compared to the prior year. Foreign currency exchange and non-recurring prior year revenue from a business held-for-sale each had an unfavorable impact of 1%.

GAAP Earnings Results

GAAP EPS was $0.14 per diluted share, versus $0.31 in the same quarter last year. GAAP operating income for the third quarter of fiscal 2025 decreased 42% to $38.7 million, compared to $67.0 million in the third quarter of fiscal 2024. GAAP operating margin was 12.2%, compared to 22.1% in the third quarter of fiscal 2024. Current quarter GAAP operating margin was unfavorably impacted by a non-recurring arbitration award.

Non-GAAP Earnings Results

Adjusted EPS increased to $0.56 per diluted share compared to $0.48 in the same quarter last year. Adjusted operating income for the third quarter of fiscal 2025 increased 11% to $110.3 million, compared to $99.6 million in the third quarter of fiscal 2024. Adjusted operating margin was 34.9% for the third quarter of fiscal 2025 compared to 33.0% in the third quarter of fiscal 2024. Adjusted operating margin was impacted by favorable volume leverage and profitability initiatives.

Segment Results

Management uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below.

Protein Sciences Segment

The Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides multiple platforms useful in various areas of protein analysis. Protein Sciences segment's third quarter fiscal 2025 net sales were $227.7 million, an increase of 6% from $214.6 million for the third quarter of fiscal 2024. As of December 31, 2023, a business within the Protein Sciences Segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's operating results for both periods presented. Organic revenue growth was 7% for the third quarter of fiscal 2025, with foreign currency exchange having an unfavorable impact of 1%. The Protein Sciences segment's operating margin increased to 45.6% in the third quarter of fiscal 2025 compared to 44.2% in the third quarter of fiscal 2024. The segment's operating margin increased primarily due to favorable volume leverage and ongoing profitability initiatives.

Diagnostics and Spatial Biology Segment

The Company's Diagnostics and Spatial Biology segment develops and provides spatial biology products, carrier screening and oncology kits, as well as exosome-based diagnostics for various pathologies, including prostate cancer. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Spatial Biology segment's third quarter fiscal 2025 net sales were $89.2 million, an increase of 2% from $87.5 million for the third quarter of fiscal 2024. Organic revenue growth was 2% for the third quarter of fiscal 2025, with foreign exchange not having a material impact. The Diagnostics and Spatial Biology segment's operating margin of 9.4% in the third quarter of fiscal 2025 was relatively consistent with the segment's prior year operating margin of 9.3%.

Use of non-GAAP Adjusted Financial Measures:

This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. These non-GAAP measures include:

• Organic revenue
• Adjusted diluted earnings per share
• Adjusted net earnings
• Adjusted tax rate
• Adjusted gross margin
• Adjusted operating income
• Adjusted operating margin
• Earnings before interest, taxes, depreciation, and amortization (EBITDA)
• Adjusted EBITDA

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP financial measure of organic revenue represents revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, the impact of businesses held-for-sale, as well as the impact of partially-owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as those revenues will not be comparative in future periods. Revenues from partially-owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculation, as those revenues are not fully attributable to the Company. There was no revenue from partially-owned consolidated subsidiaries in the fiscal years 2025 and 2024.

Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, restructuring and restructuring-related costs. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjective assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs.  Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially-owned consolidated subsidiaries as well as revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures.

The Company's non-GAAP adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including certain costs related to the transition to a new CEO, goodwill and long-lived asset impairments, and gains. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition.

The Company's non-GAAP adjusted EBITDA and adjusted net earnings, in total and on a per share basis, also excludes gain and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.

Investors are encouraged to review the reconciliations of adjusted financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.

Forward Looking Statements:

Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio­techne.com.

Contact:	David Clair, Vice President, Investor Relations & Corporate Development
	David.Clair@bio-techne.com
	612-656-4416

 

BIO-TECHNE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(In thousands, except per share data)
(Unaudited)
		QUARTER						NINE MONTHS
		ENDED						ENDED
		3/31/2025			3/31/2024			3/31/2025			3/31/2024
Net sales		$	316,181		$	303,428		$	902,671		$	852,961
Cost of sales			101,625			98,829			311,211			286,584
Gross margin			214,556			204,599			591,460			566,377
Operating expenses:
Selling, general and administrative			151,269			111,840			391,881			332,839
Research and development			24,579			25,761			73,464			72,675
Total operating expenses			175,848			137,601			465,345			405,514
Operating income			38,708			66,998			126,115			160,863
Other income (expense)			(434)			(5,914)			(4,793)			(16,835)
Earnings before income taxes			38,274			61,084			121,322			144,028
Income taxes			15,686			12,025			30,244			16,511
Net earnings		$	22,588		$	49,059		$	91,078		$	127,517
Earnings per share:
Basic		$	0.14		$	0.31		$	0.58		$	0.81
Diluted		$	0.14		$	0.31		$	0.57		$	0.79
Weighted average common shares outstanding:
Basic			157,372			157,309			158,117			157,655
Diluted			158,944			160,496			160,662			160,817

 

BIO-TECHNE CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
		3/31/2025			6/30/2024
ASSETS
Cash and equivalents		$	140,670		$	151,791
Short-term available-for-sale investments			—			1,072
Accounts receivable, net			237,140			241,394
Inventories			191,083			179,731
Current assets held-for-sale			4,700			9,773
Other current assets			53,647			33,658
Total current assets			627,240			617,419
Property and equipment, net			251,977			251,154
Right of use assets			83,744			91,285
Goodwill and intangible assets, net			1,412,311			1,479,744
Other assets			268,987			264,265
Total assets		$	2,644,259		$	2,703,867
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued expenses		$	117,445		$	112,672
Contract liabilities			32,269			27,930
Income taxes payable			3,628			3,706
Operating lease liabilities - current			14,049			12,920
Other current liabilities			1,813			2,151
Total current liabilities			169,204			159,379
Deferred income taxes			31,924			55,863
Long-term debt obligations			330,000			319,000
Operating lease liabilities			79,450			87,618
Other long-term liabilities			15,656			13,157
Stockholders' equity			2,018,025			2,068,850
Total liabilities and stockholders' equity		$	2,644,259		$	2,703,867

 

BIO-TECHNE CORPORATION
RECONCILIATION OF ADJUSTED GROSS MARGIN PERCENTAGE
(In thousands)
(Unaudited)
		QUARTER						NINE MONTHS
		ENDED						ENDED
		3/31/2025			3/31/2024			3/31/2025			3/31/2024
Total consolidated net sales		$	316,181		$	303,428		$	902,671		$	852,961
Business held-for-sale1)			—			2,093			4,152			2,093
Revenue from recurring operations		$	316,181		$	301,335		$	898,519		$	850,868
Gross margin - GAAP		$	214,556		$	204,599		$	591,460		$	566,377
Gross margin percentage - GAAP			67.9	%		67.4	%		65.5	%		66.4	%
Identified adjustments:
Costs recognized upon sale of acquired inventory		$	181		$	186		$	554		$	550
Amortization of intangibles			11,057			11,362			33,467			35,018
Stock-based compensation, inclusive of employer taxes			378			125			1,010			594
Restructuring and restructuring-related costs			364			647			7,953			1,821
Impact of business held-for-sale1)			—			272			(147)			272
Adjusted gross margin		$	226,536		$	217,191		$	634,297		$	604,632
Adjusted gross margin percentage2)			71.6	%		71.9	%		70.6	%		71.0	%

1)	Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.
2)	Adjusted gross margin percentage excludes revenue of $4,152 for the nine months ended March 31, 2025, and revenue of $2,093 for the three and nine months ended March 31, 2024. Adjusted gross margin percentage also excludes gross margin of $ (147) for the nine months ended March 31, 2025, and gross margin of $272 for the three and nine months ended March 31, 2024, for a business that has met the held-for-sale criteria.

 

BIO-TECHNE CORPORATION
RECONCILIATION OF ADJUSTED OPERATING MARGIN PERCENTAGE
(In thousands)
(Unaudited)
		QUARTER						NINE MONTHS
		ENDED						ENDED
		3/31/2025			3/31/2024			3/31/2025			3/31/2024
Total consolidated net sales		$	316,181		$	303,428		$	902,671		$	852,961
Business held-for-sale1)			—			2,093			4,152			2,093
Revenue from recurring operations		$	316,181		$	301,335		$	898,519		$	850,868
Operating income - GAAP		$	38,708		$	66,998		$	126,115		$	160,863
Operating income percentage - GAAP			12.2	%		22.1	%		14.0	%		18.9	%
Identified adjustments:
Costs recognized upon sale of acquired inventory		$	181		$	186		$	554		$	550
Amortization of intangibles			18,836			19,287			57,136			58,908
Acquisition related expenses and other			4,978			3,286			8,497			2,173
Certain litigation charges			38,927			—			40,606			—
Stock-based compensation, inclusive of employer taxes			11,629			8,358			37,504			32,810
Restructuring and restructuring-related costs			716			1,550			15,027			7,157
Impairment (recovery) of assets held-for-sale			(3,655)			—			(3,655)			6,038
Impact of business held-for-sale1)			—			(78)			479			(78)
Adjusted operating income		$	110,320		$	99,587		$	282,263		$	268,421
Adjusted operating margin percentage2)			34.9	%		33.0	%		31.4	%		31.5	%

1)	Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.
2)	Adjusted operating margin percentage excludes revenue of $4,152 for the nine months ended March 31, 2025, and revenue of $2,093 for the three and nine months ended March 31, 2024.  Adjusted gross margin also excludes operating loss of $479 for the nine months ended March 31, 2025, and operating income of $78 for the three and nine months ended March 31, 2024, for a business that has met the held-for-sale criteria.

 

BIO-TECHNE CORPORATION
NON-GAAP ADJUSTED CONSOLIDATED NET EARNINGS and EARNINGS per SHARE
(In thousands, except per share data)
(Unaudited)
		QUARTER							NINE MONTHS
		ENDED							ENDED
		3/31/2025			3/31/2024				3/31/2025			3/31/2024
Net earnings before taxes - GAAP		$	38,274		$	61,084			$	121,322		$	144,028
Identified adjustments:
Costs recognized upon sale of acquired inventory			181			186				554			550
Amortization of intangibles			18,836			19,287				57,136			58,908
Amortization of Wilson Wolf intangible assets and acquired inventory			2,491			4,208				7,471			12,623
Acquisition related expenses and other			5,109			3,432				8,923			2,609
Certain litigation charges			38,927			—				40,606			—
Stock-based compensation, inclusive of employer taxes			11,629			8,358				37,504			32,810
Restructuring and restructuring-related costs			716			1,550				15,027			7,157
Investment (gain) loss and other non-operating			—			—				—			(283)
Impairment (recovery) of assets held-for-sale			(3,655)			—				(3,655)			6,038
Impact of business held-for-sale1)			—			(78)				479			(78)
Net earnings before taxes - Adjusted		$	112,508		$	98,027			$	285,367		$	264,362
Non-GAAP tax rate			21.5	%		22.0	%			21.5	%		22.0	%
Non-GAAP tax expense		$	24,190		$	21,602			$	61,385		$	58,181
Non-GAAP adjusted net earnings		$	88,318		$	76,425			$	223,982		$	206,181
Earnings per share - diluted - Adjusted		$	0.56		$	0.48			$	1.39		$	1.28

1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.

 

BIO-TECHNE CORPORATION
NON-GAAP ADJUSTED TAX RATE
(In percentages)
(Unaudited)
		QUARTER						NINE MONTHS
		ENDED						ENDED
		3/31/2025			3/31/2024			3/31/2025			3/31/2024
GAAP effective tax rate		41.0	%		19.7	%		24.9	%		11.5	%
Discrete items		(19.5)			2.9			(1.8)			11.5
Annual forecast update		1.6			0.4			—			—
Long-term GAAP tax rate		23.1	%		23.0	%		23.1	%		23.0	%
Rate impact items
Stock based compensation		(1.0)	%		(2.0)	%		(3.8)	%		2.2	%
Other		(0.6)			1.0			2.2			(3.2)
Total rate impact items		(1.6)	%		(1.0)	%		(1.6)	%		(1.0)	%
Non-GAAP adjusted tax rate		21.5	%		22.0	%		21.5	%		22.0	%

 

BIO-TECHNE CORPORATION
SEGMENT REVENUE
(In thousands)
(Unaudited)
		QUARTER						NINE MONTHS
		ENDED						ENDED
		3/31/2025			3/31/2024			3/31/2025			3/31/2024
Protein Sciences segment revenue		$	227,687		$	214,589		$	643,774		$	616,914
Diagnostics and Spatial Biology segment revenue			89,231			87,511			256,558			235,715
Other revenue1)			—			2,093			4,152			2,093
lntersegment revenue			(737)			(765)			(1,813)			(1,761)
Consolidated revenue		$	316,181		$	303,428		$	902,671		$	852,961

1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.

 

BIO-TECHNE CORPORATION
SEGMENT OPERATING INCOME
(In thousands)
(Unaudited)
		QUARTER						NINE MONTHS
		ENDED						ENDED
		3/31/2025			3/31/2024			3/31/2025			3/31/2024
Protein Sciences segment operating income		$	103,910		$	94,829		$	271,564		$	262,777
Diagnostics and Spatial Biology segment operating income			8,423			8,104			15,940			13,189
Segment operating income			112,333			102,933			287,504			275,966
Corporate general, selling, and administrative			(2,013)			(3,346)			(5,241)			(7,545)
Adjusted operating income			110,320			99,587			282,263			268,421
Cost recognized upon sale of acquired inventory			(181)			(186)			(554)			(550)
Amortization of intangibles			(18,836)			(19,287)			(57,136)			(58,908)
Acquisition related expenses and other			(4,978)			(3,286)			(8,497)			(2,173)
Certain litigation charges			(38,927)			—			(40,606)			—
Stock-based compensation, inclusive of employer taxes			(11,629)			(8,358)			(37,504)			(32,810)
Restructuring and restructuring-related costs			(716)			(1,550)			(15,027)			(7,157)
(Impairment) recovery of assets held-for-sale			3,655			—			3,655			(6,038)
Impact of business held-for-sale1)			—			78			(479)			78
Operating income		$	38,708		$	66,998		$	126,115		$	160,863

1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.

 

BIO-TECHNE CORPORATION
RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA
(In thousands)
(Unaudited)
	QUARTER						NINE MONTHS
	ENDED						ENDED
	3/31/2025			3/31/2024			3/31/2025			3/31/2024
Net earnings	$	22,588		$	49,059		$	91,078		$	127,517
Net interest expense (income)		981			3,293			3,031			10,808
Depreciation and amortization		27,571			27,310			82,792			83,654
Income taxes		15,686			12,025			30,244			16,511
EBITDA		66,826			91,687			207,145			238,490
Costs recognized upon sale of acquired inventory		181			186			554			550
Amortization of Wilson Wolf intangible assets and acquired inventory		2,491			4,208			7,471			12,623
Acquisition related expenses and other		5,109			3,432			8,923			2,609
Certain litigation charges		38,927			—			40,606			—
Stock-based compensation, inclusive of employer taxes		11,629			8,358			37,504			32,810
Restructuring and restructuring-related costs		716			1,550			15,027			7,157
Investment (gain) loss and other non-operating		—			—			—			(283)
Impairment (recovery) of assets held-for-sale		(3,655)			—			(3,655)			6,038
Impact of business held-for-sale1)		—			(78)			479			(78)
Adjusted EBITDA	$	122,224		$	109,343		$	314,054		$	299,916

1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.

 

BIO-TECHNE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
		NINE MONTHS
		ENDED
		3/31/2025			3/31/2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings		$	91,078		$	127,517
Adjustments to reconcile net earnings to net cash provided by operating activities
Depreciation and amortization			82,792			83,654
Costs recognized on sale of acquired inventory			554			550
Deferred income taxes			(18,825)			(29,896)
Stock-based compensation expense			36,283			30,979
Fair value adjustment to available-for-sale investments			—			(283)
(Gain) Loss on equity method investment			169			6,042
Asset impairment restructuring			9,961			—
Fair value adjustment to contingent consideration payable			—			(3,500)
Impairment (recovery) of assets held-for-sale			(3,655)			6,038
Other operating activities			(9,002)			2,384
Net cash provided by (used in) operating activities			189,355			223,485
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of available-for-sale investments			1,085			23,759
Purchases of available-for-sale investments			—			(5,526)
Additions to property and equipment			(26,116)			(44,897)
Acquisitions, net of cash acquired			—			(169,707)
Distributions from (Investments in) Wilson Wolf			2,653			2,149
Investment in Spear Bio			(15,000)			—
Proceeds from sale of assets held-for-sale			1,789			—
Net cash provided by (used in) investing activities			(35,589)			(194,222)
CASH FLOWS FROM FINANCING ACTIVITIES
Cash dividends			(38,004)			(37,792)
Proceeds from stock option exercises			45,513			38,001
Long-term debt activity, net			11,000			39,000
Re-purchases of common stock			(175,674)			(80,042)
Taxes paid on RSUs and net share settlements			(6,288)			(21,470)
Net cash provided by (used in) financing activities			(163,453)			(62,303)
Effect of exchange rate changes on cash and cash equivalents			(1,434)			(7,616)
Net increase (decrease) in cash and cash equivalents			(11,121)			(40,656)
Cash and cash equivalents at beginning of period			151,791			180,571
Cash and cash equivalents at end of period		$	140,670		$	139,915

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-third-quarter-fiscal-2025-results-302448086.html

SOURCE Bio-Techne Corporation

FAQ

What were Bio-Techne's (TECH) Q3 2025 earnings per share?

Bio-Techne reported GAAP EPS of $0.14 and adjusted EPS of $0.56 for Q3 2025.

How much did Bio-Techne's (TECH) revenue grow in Q3 2025?

Bio-Techne's organic revenue grew 6% (4% reported) to $316.2 million in Q3 2025.

What was Bio-Techne's (TECH) operating margin in Q3 2025?

Bio-Techne's adjusted operating margin was 34.9%, while GAAP operating margin was 12.2% in Q3 2025.

How did Bio-Techne's (TECH) Protein Sciences segment perform in Q3 2025?

The Protein Sciences segment achieved 7% organic growth with revenue of $227.7 million, driven by improved pharma end market conditions.

What factors affected Bio-Techne's (TECH) GAAP operating margin in Q3 2025?

The GAAP operating margin was negatively impacted by a non-recurring arbitration award, declining to 12.2% from 22.1% in the prior year.